Reply: Anthithrombotic therapy and vascular access site: A choice not mutually exclusive.
Structural and Congenital Heart Center, Hackensack University Medical Center, Hackensack, NJ, USA.
Tilak K R
TK
Pasala
Center for Health Care Research and Policy, MetroHealth/Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Shari
S
Bolen
Division of Cardiovascular Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA. Electronic address: fred.welt@hsc.utah.edu.
Frederick G P
FG
Welt
D000925:Anticoagulants; D000991:Antithrombins; D006493:Heparin; D006629:Hirudins; D006801:Humans; D010446:Peptide Fragments; D062645:Percutaneous Coronary Intervention; D011994:Recombinant Proteins; D016896:Treatment Outcome
D000925:Anticoagulants; D000991:Antithrombins; D006629:Hirudins; D010446:Peptide Fragments; D011994:Recombinant Proteins; D006493:Heparin
Bivalirudin; Heparin; Percutaneous coronary intervention; Radial